Liquid formulation of long acting insulinotropic peptide conjugate

A liquid formulation of a long-acting insulinotropic peptide conjugate, the liquid formulation consisting essentially of:

• the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide and an immunoglobulin Fc region are linked by polyethylene glycol;
• and
• an albumin-free stabilizer, wherein the stabilizer comprises citrate buffer, mannitol, polysorbate 20, and sodium chloride,
• wherein the insulinotropic peptide is giucagon-like peptide-1, glucagon-like pepetide-2, exendin-3, exendin-4 or imidazo-acetyl exendin-4;
• wherein the buffer has a pH of 5.2 to 7.0;
• and
• wherein the polysorbate 20 has a concentration of 0.001% to 0.05% (w/v).

A multiple-use liquid formulation of a long-acting insulinotropic peptide conjugate, the multiple-use liquid formulation consisting essentially of:

• a pharmaceutically effective amount of the long-acting insulinotropic peptide conjugate wherein an insulinotropic peptide, which is a physiologically active peptide, is linked to an immunoglobulin Fc region;
• an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent;
• and
• one or more preservatives selected from the group consisting of m-cresol, phenol, and benzyl alcohol,
• wherein the insulinotropic peptide is glucagon-like peptide-1, glucagon-like peptide-2, exendin-3 ,exendin-4 or imidazo-acetyl exendin-4;
• wherein the buffer has a pH of 5.2 to 7.0;
• and
• wherein the polysorbate 20 has a concentration of 0.001% (w/v) to 0.05% (w/v).